semaglutide cardiovascular news SELECT: Semaglutide's Impact on CVD Events Emerges Quickly Heart disease: Semaglutide may reduce

Researchers examined data from multiple studies, including large patient populations undergoing procedures while taking GLP-1 drugs

A bezoar may become too big to pass through the outlet at the bottom of your stomach

Additionally, if you're experiencing symptoms such as persistent abdominal pain, blood in your stools, excessive weight loss, or any symptoms that significantly interfere with your day-to-day activities, it's important to speak with your prescribing physician, as you may need to temporarily reduce your GLP-1 dose and be screened for more serious causes of your symptoms, such as IBD or colorectal cancer

Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors, which is thought to explain its larger average weight loss in clinical trials

All aspects of care, including initial evaluations, laboratory testing , follow-up visits, and dose adjustments, are coordinated within one clinic to ensure continuity and close monitoring

Most women over 40 see the biggest GLP-1 results over months, not days